F S&P 500
5,204.00 -2.50 (-0.05%) F Dow Jones
39,007.00 +10.00 (+0.03%) F Nasdaq
18,167.00 -28.50 (-0.16%) E-mini Russell 2000 Index Futur
2,070.50 -0.60 (-0.03%) Petróleo
78.34 -0.14 (-0.18%) Oro
2,328.10 -3.10 (-0.13%)
Tyra Biosciences, Inc. (TYRA)
Fuera de horario:
Tyra Biosciences, Inc.
2656 State Street
Carlsbad, CA 92008
United States
619 728 4760
https://tyra.bio
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 49
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Todd Harris Ph.D. | Co-Founder, President, CEO, Secretary, Treasurer & Director | 1.07M | N/D | 1979 |
| Mr. Alan Fuhrman | Chief Financial Officer | 763.09k | N/D | 1957 |
| Dr. Hiroomi Tada M.D., Ph.D. | Chief Medical Officer | 816.31k | N/D | 1964 |
| Mr. Daniel Bensen | Co-Founder & COO | 630.8k | N/D | 1976 |
| Dr. Robert L. Hudkins Ph.D. | Chief Technology Officer | N/D | N/D | 1956 |
| Dr. Ronald V. Swanson Ph.D. | Chief Scientific Officer | 536.19k | N/D | 1964 |
| Mr. Ali D. Fawaz J.D. | General Counsel | 629.23k | N/D | N/D |
| Ms. Sarah Honig | Vice President of Corporate Development & Strategy | N/D | N/D | N/D |
| Dr. Piyush R. Patel Ph.D. | Chief Development Officer | N/D | N/D | 1966 |
| Amy Conrad | Investor Contact | N/D | N/D | N/D |
Descripción
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Tyra Biosciences, Inc. a partir del 1 de mayo de 2024 es 7. Las puntuaciones principales son Auditoría: 4; Junta: 6; Derechos del accionista: 8; Compensación: 8.
